Ultragenyx climbs after US FDA approves gene therapy
17/09/2026 20:58
BUZZ-Ultragenyx climbs after US FDA approves gene therapy Updates
** Ultragenyx Pharmaceutical RARE.O shares rise 12.8% to $14.52
** U.S Food and Drug Administration has approved Ultragenyx's gene therapy, Fayuvi, as the first treatment for children with Sanfilippo syndrome Type A
** The condition damages the brain and nervous system because the body cannot properly break down heparan sulfate, leading to a gradual loss of cognitive, speech and motor skills
** Children who received Fayuvi maintained or improved cognitive function compared with untreated patients, according to the FDA
** Including session's moves, stock has fallen ~40% YTD
(Reporting by Aatreyee Dasgupta and Kamal Choudhury)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx